Area of research
Genetics · Epidemiology
Research interest
Research interests include Medicine, Inflammatory bowel disease, Internal medicine, Ulcerative colitis, Gastroenterology, and Cohort.
The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission
Biomarkers in IBD: What to Utilize for the Diagnosis?
HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis
Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study
Role of ER Stress Mediated Unfolded Protein Responses and ER Stress Inhibitors in the Pathogenesis of Inflammatory Bowel Disease
Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
Female reproductive health and inflammatory bowel disease: A practice-based review
Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease
Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study
Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors – A cross-sectional study
PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability
The use of 5‐aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow‐up – an Epi‐IBD study
Peptidomic and proteomic analysis of stool for diagnosing IBD and deciphering disease pathogenesis
Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas
Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
Perception of the COVID-19 Pandemic Among Patients With Inflammatory Bowel Disease in the Time of Telemedicine: Cross-Sectional Questionnaire Study
Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario
Correction: PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability
Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case–Control IG-IBD Study
Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients
Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients
Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab
Diffusion-weighted magnetic resonance for assessing fibrosis in Crohn’s disease
Inflammatory Bowel Disease Therapies Adversely Affect Fertility in Men- A Systematic Review and Meta-analysis
Late-onset Crohn’s disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease ‘AGED’ study
Terminal ileum ileoscopy and histology in patients undergoing high‐definition colonoscopy with virtual chromoendoscopy for chronic nonbloody diarrhea: A prospective, multicenter study
Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes